- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Neoprobe arranges Israeli agent plant
Neoprobe is establishingan Israeli subsidiary to run a radiolabeling facility for monoclonalantibody agents used in its nuclear probe technology (see above).The U.S. firm signed a memorandum of understanding with the Israelifirm Rotem Industries in
Neoprobe is establishingan Israeli subsidiary to run a radiolabeling facility for monoclonalantibody agents used in its nuclear probe technology (see above).The U.S. firm signed a memorandum of understanding with the Israelifirm Rotem Industries in January. Neoprobe will own 95% of Neoprobe-Israeland Rotem the rest.
Located near Temed, Neoprobe-Israel will produce radiolabeledantibodies for use with its RIGS technology in Europe and Israel.The company will also serve as a secondary source of supply forRIGS agents, in addition to Nordion of Canada. Neoprobe has signeda long-term supply agreement with Nordion.
The move is a logical follow-up to its acquisition of MonoCarbAB of Sweden last December, said Neoprobe president David Bupp.
"Neoprobe now has complete control of all aspects of manufacturingand distributing RIGS surgical system targeting agents,"he said.
The agreement with Rotem is contingent on the government ofIsrael providing $3 million in guarantees to help fund the facilityand clinical testing of agents developed there.
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
AI Adjudication Bolsters Chest CT Assessment of Lung Adenocarcinoma
April 11th 2024The inclusion of simulated adjudication for resolving discordant nodule classifications in a deep learning model for assessing lung adenocarcinoma on chest CT resulted in a 12 percent increase in sensitivity rate.
